Stock analysts at StockNews.com initiated coverage on shares of IRIDEX (NASDAQ:IRIX – Get Free Report) in a research report issued on Thursday. The brokerage set a “hold” rating on the medical equipment provider’s stock.
IRIDEX Stock Up 10.7 %
NASDAQ:IRIX opened at $0.94 on Thursday. The company has a quick ratio of 0.85, a current ratio of 1.54 and a debt-to-equity ratio of 0.55. The stock has a market capitalization of $15.79 million, a price-to-earnings ratio of -1.40 and a beta of 0.74. IRIDEX has a 52 week low of $0.78 and a 52 week high of $3.53. The stock’s fifty day moving average is $1.22 and its two-hundred day moving average is $1.51.
IRIDEX (NASDAQ:IRIX – Get Free Report) last issued its quarterly earnings results on Thursday, March 27th. The medical equipment provider reported ($0.05) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.05). IRIDEX had a negative net margin of 22.79% and a negative return on equity of 192.95%. The business had revenue of $12.70 million for the quarter, compared to analysts’ expectations of $12.80 million.
About IRIDEX
IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. It offers laser consoles, such as Cyclo G6 laser system for use in the treatment of glaucoma; IQ 532 and IQ 577 laser systems, which are used for the treatment of retinal disorders; and OcuLight TX, OcuLight SL, OcuLight SLx, OcuLight GL, and OcuLight GLx laser photocoagulation systems that are used to treat proliferative diabetic retinopathy, macular holes, retinal tears, and detachments.
See Also
- Five stocks we like better than IRIDEX
- What Are Treasury Bonds?
- Quantum Computing: The $6.5 Billion Opportunity You Can’t Ignore
- 3 REITs to Buy and Hold for the Long Term
- Are Tariffs Threatening Disney’s Comeback Story?
- How Investors Can Find the Best Cheap Dividend Stocks
- Is Alphabet a Generational Buying Opportunity at These Levels?
Receive News & Ratings for IRIDEX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IRIDEX and related companies with MarketBeat.com's FREE daily email newsletter.
